Where Eden Health, OrderlyMeds, and the Rest of the FDA's Warning-Letter List Stand Right Now

Last updated: 2026-07-08

Two FDA response deadlines have now quietly expired with no public trace of a response from either company. Eden Health and OrderlyMeds both received warning letters dated June 8, 2026, both had roughly 15 business days to respond — a window that closed around June 29-30 — and as of today, neither company has posted a public response, and the FDA hasn't posted any closeout letter or escalation for either one.

That brings the running total to at least five telehealth weight-loss companies now connected to FDA warning letters across three separate enforcement waves since September 2025. If you're using one of these programs, or comparing options, here's what's actually confirmed, company by company — not what a forum post or a competing review site claims.

What's New: OrderlyMeds Just Got Confirmed

OrderlyMeds LLC received a warning letter dated June 8, 2026 (FDA case reference #728291) — the same batch date as Eden Health's letter. According to the FDA's own letter, OrderlyMeds is cited for two distinct problems, not one:

Sourcing misrepresentation. OrderlyMeds' logo appeared on compounded semaglutide and tirzepatide product labels in a way that implied OrderlyMeds itself was the compounding pharmacy — when it wasn't. That's the kind of "who actually made this" transparency issue the FDA has been hammering across every wave of this enforcement push.
False licensing claims. The letter also cites marketing language describing OrderlyMeds as an "FDA-licensed pharmacy" — a claim the FDA disputes, since the FDA doesn't "license" pharmacies in the way that phrase implies, and no compounded drug marketed this way carries FDA approval regardless of which pharmacy made it.

Until this letter surfaced, OrderlyMeds hadn't been individually confirmed as part of any FDA enforcement wave. It now joins Eden Health as one of two companies in the June 8 batch with an expired, unanswered response window.

Eden Health: Now About a Week Past Its Deadline With No Trace

Eden Health International Inc. (dba Eden) received its warning letter the same day — June 8, 2026, FDA case reference #728279 — citing the now-familiar "same active ingredient as Wegovy®/Ozempic®" and "same active ingredient as Mounjaro®/Zepbound®" language. That phrasing implies a level of FDA evaluation and equivalence that compounded drugs, made under a narrow shortage-related exemption, have never actually received.

Eden's response deadline passed around June 29-30. As of this week, there's no closeout letter, no public statement, and no discoverable response anywhere — not on FDA's warning-letter index, not in news coverage, not on Eden's own press page. That silence is unusual enough to be worth watching directly rather than assuming a search engine simply hasn't indexed a response yet: if a company ignores a warning letter outright, the FDA's next steps can include an injunction or a product seizure referral, and those escalations don't always come with much advance public notice.

To be clear about what this doesn't mean: a warning letter is not a shutdown order, and an unanswered deadline is not the same as an enforcement action. It means the compliance question is open longer than is typical, not that action is guaranteed or imminent.

The Full Roster: Every Tracked Provider's Status

Here's where things stand, name by name, based on direct review of FDA's warning-letter records and cross-checked news coverage. Confirmed means an FDA warning letter with a specific case number exists. Everything else is stated as exactly what it is — unresolved, or simply not found.

| Provider | Status |

|---|---|

| Eden Health | Confirmed. Letter #728279, dated June 8, 2026. Response deadline passed with no public trace. |

| OrderlyMeds | Confirmed. Letter #728291, dated June 8, 2026. Response deadline passed with no public trace. |

| MEDVi | Confirmed. Letter #721455, dated February 20, 2026 — an earlier wave, not the June batch. MEDVi has said the flagged marketing was produced by a third-party affiliate agency, not by MEDVi directly. |

| SkinnyRx | Confirmed. Letter #717989, dated February 20, 2026 — same earlier wave as MEDVi. |

| AltRx (Trinity HealthCare Supply, LLC dba AltRx) | Confirmed. Letter #728236, dated June 8, 2026 — same batch as Eden Health and OrderlyMeds. Covered in more detail in our MEDVi/AltRx warning-letter wave piece. |

| Strut Health | Confirmed to carry a letter, but from an earlier wave (February 2026 or September 2025) — not the June 2026 batch. Lower-confidence detail on exact date; worth checking FDA.gov directly if you need the specific letter. |

| PeterMD | No discoverable letter found in any wave as of this week's check. |

| Hone Health | No discoverable letter found in any wave as of this week's check. |

| Brightmeds | No discoverable letter found in any wave as of this week's check. |

| Sprout Health | Not yet individually confirmed clear against the June batch — still an open question as of today. |

| TrimRx | Not implicated in any wave checked so far. |

| Ro.co | No letter surfaced in our research, but not yet individually cross-checked with the same rigor as the names above — treat as unconfirmed rather than cleared. |

| SHED | Same caveat as Ro.co — no letter surfaced, but not individually cross-checked against the June batch specifically. |

| Hims & Hers | Not implicated in a warning letter. Different situation entirely: following its March 9, 2026 settlement with Novo Nordisk, Hims wound down compounded semaglutide for new patients and shifted its default funnel to insurance-billed, branded Wegovy/Zepbound. |

A few names worth ruling out explicitly, since they've circulated in industry chatter without a documented letter behind them: Trimi, Omzo, and bmiMD have no FDA warning letter on record as of this writing, despite speculation connecting them to this enforcement cycle. "Trinity Meds" is also worth flagging separately — it's a distinct company from "Trinity HealthCare Supply, LLC dba AltRx," and the similar names have caused some confusion in secondhand coverage.

Separately, the FDA's broader June 8-16 batch included 25 total warning letters to telehealth companies, and only three names from that full batch have been individually confirmed in press coverage: Medica Weight Loss, Ready Med, and Clover Meds. None of those three are affiliate partners tracked on this site — they're included here only because they establish that this is a wide, ongoing sweep, not a small handful of isolated cases.

Why "No Letter Found" Isn't the Same as "Cleared"

It's tempting to read a "no discoverable letter" status as good news and move on. Worth being precise about what that actually means: the FDA's public warning-letter database is not a complete, real-time list of every enforcement action taken. Letters can lag behind the date they were actually sent, and the agency doesn't always publicize every step of an enforcement process, especially once a company is already in a resolution or escalation process behind the scenes. Absence of a hit on a search is evidence of "we didn't find one," not proof of "there isn't one."

That's exactly why this is a tracker and not a one-time verdict. If you're evaluating any of the names above, or you're already a customer of one, the responsible move is to check the primary source yourself rather than treat any single article — including this one — as the final word.

The Bigger Pattern: Three Waves in Under a Year

Zoom out, and the individual letters matter less than the pattern they form. This is the third major FDA enforcement wave against telehealth GLP-1 marketing since September 2025 — roughly 58 letters in that first wave, about 30 more in March 2026, and 25 in the June 2026 batch that produced the Eden Health, OrderlyMeds, and AltRx letters. Every single letter in this cycle cites some version of the same core problem: marketing language ("same active ingredient as," "clinically proven," "FDA-licensed") that creates a false impression of FDA evaluation or approval for a compounded product that has never gone through that process.

This enforcement pressure is also arriving at the same time the underlying legal basis for large-scale compounding is being wound down on its own separate track. The FDA's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the rule that would end the shortage-based exemption allowing mass compounding of these drugs in the first place — has its public comment period confirmed through July 30, 2026. We've covered what that deadline actually changes, and what to consider instead, in more detail in our piece on the compounding deadline.

Put together: even a provider that never receives a single warning letter is operating in a category where the entire compounding exemption it depends on is under active threat. The marketing-claims enforcement and the compounding-exemption wind-down are two different regulatory tracks, but they're both pointing the same direction.

What a Warning Letter Actually Means for You

If you're currently enrolled with any of the confirmed companies above, a few things are worth separating clearly:

It's not a recall. A warning letter addresses marketing claims and business practices, not a specific safety defect in a specific batch of medication.
It doesn't stop your prescription automatically. Companies typically keep operating and shipping product while a warning letter is pending, unless the FDA escalates to an injunction or seizure — which hasn't happened for any name on this list as of today.
It does tell you something about the marketing that got you there. If the claims that convinced you to sign up — "same as the brand name," "clinically proven," aggressive price comparisons — match the language the FDA is citing, that's worth weighing when you decide whether to continue, especially since none of it changes the underlying legal uncertainty around compounded access.

If you're mid-treatment and otherwise doing fine, this is a conversation for your prescriber, not a reason to stop a medication abruptly on your own — especially with GLP-1s, where sudden discontinuation has its own effects on appetite and blood sugar regulation.

How to Check FDA.gov Yourself

Don't take this article's word for any of it longer than it takes you to verify. Here's the actual process:

Search "FDA warning letters" and go to the agency's own database under Inspections, Compliance, Enforcement, and Criminal Investigations.
Filter by date range. For this wave, filter to June 2026; for the earlier wave, February 2026.
Search by the company's legal name, not its consumer-facing brand. Eden Health is filed as "Eden Health International Inc. dba Eden." AltRx is filed under "Trinity HealthCare Supply, LLC." If you only search the brand name, you may miss the filing.
Every letter carries a specific case number (the FDA calls it a MARCS-CMS reference). If anyone — a forum post, a competitor's review site, or this article — claims a company "got a warning letter," ask for that number. A real claim has one.
If you can't find a letter, treat that as unconfirmed, not cleared. The index isn't instant and isn't exhaustive.

Red Flags Worth Checking Regardless of Which Provider You're Considering

Is the compounding pharmacy actually named? If a telehealth brand's own logo appears on the product label with no separate compounder disclosed, that's the exact sourcing-transparency violation cited in the OrderlyMeds letter.
Does the marketing say "FDA-licensed," "FDA-approved," or "same active ingredient as [brand]"? These specific phrases are the recurring target of every wave of this enforcement.
Is a licensed prescriber actually reviewing your case, or is intake handled entirely by an automated form?
Is pricing transparent, without dose-escalation structures that quietly raise your monthly cost as your prescribed dose increases?
Is the provider listed with LegitScript or a similar telehealth verification service? Not a guarantee, but a useful independent screen.

Frequently Asked Questions

Is Eden Health or OrderlyMeds shutting down?

Not based on anything confirmed as of today. Both have unanswered warning letters and expired response windows, which is a compliance risk worth watching, not evidence that either company is closing or has stopped shipping product.

Should I switch providers immediately if my provider is on the confirmed list?

That's a personal decision based on your comfort with the underlying regulatory uncertainty, not a requirement — a warning letter doesn't force a company to stop serving existing patients. If you're uneasy, talk to your prescriber about options rather than making a unilateral change.

Why do "no letter found" and "not yet confirmed clear" appear as two different categories in your tracker?

Because they're not the same thing, and collapsing them would overstate what we actually know. "No letter found" means we checked and didn't find one. "Not yet confirmed clear" means we haven't finished checking that specific name against the most recent batch. Being precise about that difference is the entire point of a tracker like this.

How often will this update?

As new information becomes confirmed — a company's response is posted, an escalation occurs, or a previously unconfirmed name gets resolved either way — we'll update this piece rather than publish a new one, so the "Last updated" date at the top is the one to check.

If You'd Rather Sidestep the Uncertainty Entirely

Given how much is still unresolved across this roster — two open, unanswered letters, several unconfirmed names, and a compounding exemption that's being phased out regardless of any individual letter — it's worth at least pricing out brand-name access before assuming compounded is your only realistic option. Sequence by Found and Noom Med have both built insurance-navigation and prior-authorization support specifically around brand-name Wegovy and Zepbound, rather than relying on the compounding exemption this entire enforcement cycle is about. Neither has appeared in any warning-letter wave covered here.

Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, we may earn a small commission at no extra cost to you. We only recommend products we genuinely believe in. This helps support our work and allows us to continue providing free content.